Influence of COVID-19 Glioblastoma Market Application, Revenue, Excessive Growth, and Region-Forecasts 2025

Global Glioblastoma Market: Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) – Forecast till 2025

The Global Glioblastoma Market is expected to register a CAGR of 7.40% to reach 1,643.4 million by 2025. Glioblastoma is a type of brain tumor. The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.

Download Sample of This Strategic Report-

Market Dynamics

The increasing incidence rate of glioblastoma is expected to fuel the growth of the global glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.


The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.

Regional Analysis

The global glioblastoma market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is likely to dominate the global glioblastoma market. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.

Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.

Download Sample of This Strategic Report-

Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.

Key Players

The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.

In May 2019, Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.In January 2018, Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers.

Request For Full Report-

In November 2016, Sun Pharma acquired Biosintez, a Russian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical products.

Market Segmentation

Global Glioblastoma Market, by Type

Primary Glioblastoma

Secondary Glioblastoma

Global Glioblastoma Market, by Treatment

Surgical Procedure

Radiation Therapy



Global Glioblastoma Market, by End User


Specialty Clinics and Centers


Global Glioblastoma Market, by Region


North America



Latin America


Western Europe






Rest of Western Europe

Eastern Europe






South Korea

Rest of Asia-Pacific

Middle East & Africa

Middle East


Available Additional Customizations

Mega Trends in the Market

Glioblastoma Market: Challenges

Intended Audience

Pharmaceutical companies

Contract research manufacturing organizations

Research & development organizations

Academic institutes

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products’ demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research
Phone: +1 313 462 0609

James Bullock is a Research Expert with a demonstrated history of working in the professional training & coaching industry. Strong professional skilled in business strategy , Strategic Planning, Research Strategy, and Marketing. also have interest in new innovations and technology

Leave a Reply